Difference between revisions of "Team:British Columbia/Description"
Ahmedhatem (Talk | contribs) |
Ahmedhatem (Talk | contribs) |
||
| Line 63: | Line 63: | ||
<p> | <p> | ||
Distributing metabolic pathways between microbial community members has shown significant potential for the large-scale production of complex, biologically-derived chemical products. Our goal is to address the challenge of regulating population dynamics in a synthetic microbial consortium, by improving the rate of production of naringenin and its pharmaceutically significant derivative, kaempferol, which has anti-cancer properties. This is done by distributing the synthesis of kaempferol between two E. coli strains and optimizing their relative proportions in co-culture. To optimize population dynamics for the production of kaempferol, we regulated the ratio of the two strains using GP2, a transcriptional inhibitor, under the control of a biosensor responsive to the pathway intermediate naringenin. This couples cell growth with the concentration of naringenin, allowing the co-culture to self-optimize based on pathway intermediate abundance. Using our system, we have demonstrated a novel way to optimize microbial polycultures for the synthesis of metabolically complex compounds. | Distributing metabolic pathways between microbial community members has shown significant potential for the large-scale production of complex, biologically-derived chemical products. Our goal is to address the challenge of regulating population dynamics in a synthetic microbial consortium, by improving the rate of production of naringenin and its pharmaceutically significant derivative, kaempferol, which has anti-cancer properties. This is done by distributing the synthesis of kaempferol between two E. coli strains and optimizing their relative proportions in co-culture. To optimize population dynamics for the production of kaempferol, we regulated the ratio of the two strains using GP2, a transcriptional inhibitor, under the control of a biosensor responsive to the pathway intermediate naringenin. This couples cell growth with the concentration of naringenin, allowing the co-culture to self-optimize based on pathway intermediate abundance. Using our system, we have demonstrated a novel way to optimize microbial polycultures for the synthesis of metabolically complex compounds. | ||
| − | |||
</p> | </p> | ||
| + | <img src="https://static.igem.org/mediawiki/2018/f/fa/T--British_Columbia--glucose-kaempferol-graphic.png" | ||
| + | style=" | ||
| + | display: block; | ||
| + | max-width:500px; | ||
| + | max-height:500px; | ||
| + | width: auto; | ||
| + | height: auto;"> | ||
| + | |||
</body> | </body> | ||
</html> | </html> | ||
Revision as of 01:34, 18 October 2018
Distributing metabolic pathways between microbial community members has shown significant potential for the large-scale production of complex, biologically-derived chemical products. Our goal is to address the challenge of regulating population dynamics in a synthetic microbial consortium, by improving the rate of production of naringenin and its pharmaceutically significant derivative, kaempferol, which has anti-cancer properties. This is done by distributing the synthesis of kaempferol between two E. coli strains and optimizing their relative proportions in co-culture. To optimize population dynamics for the production of kaempferol, we regulated the ratio of the two strains using GP2, a transcriptional inhibitor, under the control of a biosensor responsive to the pathway intermediate naringenin. This couples cell growth with the concentration of naringenin, allowing the co-culture to self-optimize based on pathway intermediate abundance. Using our system, we have demonstrated a novel way to optimize microbial polycultures for the synthesis of metabolically complex compounds.
